Oncocyte to Release First Quarter 2025 Results on May 12, 2025

5/7/25 4:10:00 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $OCX alert in real time by email

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar.

An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com.

About Oncocyte

Oncocyte is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.oncocyte.com/ for more information.

Investor Contact:

Doug Farrell

LifeSci Advisors LLC

[email protected]

Get the next $OCX alert in real time by email

Date	Price Target	Rating	Analyst
3/28/2025	$5.00	Buy	Lake Street
5/24/2022		Overweight → Equal-Weight	Stephens
3/14/2022		Overweight → Sector Weight	KeyBanc Capital Markets
3/11/2022	$11.00 → $6.00	Buy	Lake Street
3/11/2022	$5.00 → $4.00	Buy	Needham
1/7/2022	$3.10	Overweight	Stephens & Co.
1/6/2022	$3.10	Overweight	Piper Sandler
12/16/2021	$7.00 → $5.00	Buy	Needham

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Chat with this insight

Recent Analyst Ratings for $OCX

$OCX SEC Filings

Oncocyte Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

SEC Form 424B3 filed by Oncocyte Corporation

SEC Form EFFECT filed by Oncocyte Corporation

$OCX Leadership Updates

Live Leadership Updates

Veradigm Announces Board Expansion and Changes

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

$OCX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

$OCX Press Releases

Fastest customizable press release news feed in the world

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

$OCX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on OncoCyte with a new price target

OncoCyte downgraded by Stephens

OncoCyte downgraded by KeyBanc Capital Markets

$OCX Financials

Live finance-specific insights

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte Provides Positive Update on Clinical Trial Progress

STAAR Surgical Announces Changes to Board of Directors

$OCX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

SEC Form SC 13G filed by Oncocyte Corporation

Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

$OCX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Financial Officer James Andrea S.

SEC Form 4 filed by VP ACCT, Cntlr, Treasurer, PAO Liu James Yang

SEC Form 4 filed by CEO and President Riggs Josh

Recent Analyst Ratings for
$OCX

$OCX
SEC Filings

$OCX
Leadership Updates

$OCX
Insider Purchases

$OCX
Press Releases

$OCX
Analyst Ratings

$OCX
Financials

$OCX
Large Ownership Changes

$OCX
Insider Trading